Clinical Trial Update: Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab in combination with bevacizumab for brain metastases in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Brain Metastases, Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN